220 related articles for article (PubMed ID: 35172273)
21. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
Morales Murillo S; Gasol Cudos A; Veas Rodriguez J; Canosa Morales C; Melé Olivé J; Vilardell Villellas F; Sanchez Guzman DR; Iglesias Martínez E; Salud Salvia A
Breast; 2021 Apr; 56():35-41. PubMed ID: 33601299
[TBL] [Abstract][Full Text] [Related]
22. 21-Gene recurrence score predictive for prognostic benefit of radiotherapy in patients age ≥ 70 with T1N0 ER/PR + HER2- breast cancer treated with breast conserving surgery and endocrine therapy.
Chevli N; Haque W; Tran KT; Farach AM; Schwartz MR; Hatch SS; Butler EB; Teh BS
Radiother Oncol; 2022 Sep; 174():37-43. PubMed ID: 35772577
[TBL] [Abstract][Full Text] [Related]
23. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
24. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
[TBL] [Abstract][Full Text] [Related]
25. The Prognostic Significance of the Oncotype DX Recurrence Score in T
Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
[TBL] [Abstract][Full Text] [Related]
26. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis.
Ding S; Wu J; Lin C; Andriani L; Goh C; Chen W; Li Y; Shen K; Zhu L
Oncologist; 2019 Nov; 24(11):e1014-e1023. PubMed ID: 31019021
[TBL] [Abstract][Full Text] [Related]
28. The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting.
Choi JDW; Hughes TMD; Marx G; Boyages J; Rutovitz J; Hasovits C; Parasyn A; Edirimanne S; Ngui NK
Breast J; 2022; 2022():1199245. PubMed ID: 35711899
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
[TBL] [Abstract][Full Text] [Related]
30. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
31. Molecular Drivers of Onco
Buus R; Sestak I; Kronenwett R; Ferree S; Schnabel CA; Baehner FL; Mallon EA; Cuzick J; Dowsett M
J Clin Oncol; 2021 Jan; 39(2):126-135. PubMed ID: 33108242
[TBL] [Abstract][Full Text] [Related]
32. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
33. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
[TBL] [Abstract][Full Text] [Related]
34. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
35. Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors.
Sestak I; Dowsett M; Ferree S; Baehner FL; Cuzick J
Breast Cancer Res Treat; 2016 Aug; 159(1):71-8. PubMed ID: 27447876
[TBL] [Abstract][Full Text] [Related]
36. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
[TBL] [Abstract][Full Text] [Related]
37. The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.
Filipits M; Rudas M; Kainz V; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Regitnig P; Halper S; Hulla W; Egle D; Barron S; Loughman T; O'Leary D; Gallagher WM; Hlauschek D; Gnant M; Dubsky P
Clin Cancer Res; 2021 Nov; 27(21):5931-5938. PubMed ID: 34380638
[TBL] [Abstract][Full Text] [Related]
38. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Ibraheem AF; Press DJ; Olopade OI; Huo D
Cancer; 2019 Jan; 125(2):213-222. PubMed ID: 30387876
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
40. Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Heindl A; Sestak I; Naidoo K; Cuzick J; Dowsett M; Yuan Y
J Natl Cancer Inst; 2018 Feb; 110(2):. PubMed ID: 28859291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]